114 related articles for article (PubMed ID: 37666354)
21. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
22. Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants.
Rutella S; Rumi C; Laurenti L; Pierelli L; Sora' F; Sica S; Leone G
Br J Haematol; 2000 Jan; 108(1):105-15. PubMed ID: 10651733
[TBL] [Abstract][Full Text] [Related]
23. Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma.
Rueff J; Medinger M; Heim D; Passweg J; Stern M
Biol Blood Marrow Transplant; 2014 Jun; 20(6):896-9. PubMed ID: 24631739
[TBL] [Abstract][Full Text] [Related]
24. Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation - a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients.
Rundgren IM; Ersvær E; Ahmed AB; Ryningen A; Bruserud Ø
BMC Immunol; 2019 Nov; 20(1):39. PubMed ID: 31703617
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study.
Uy GL; Goyal SD; Fisher NM; Oza AY; Tomasson MH; Stockerl-Goldstein K; DiPersio JF; Vij R
Bone Marrow Transplant; 2009 May; 43(10):793-800. PubMed ID: 19029964
[TBL] [Abstract][Full Text] [Related]
26. Autologous stem cell transplantation in multiple myeloma patients over 70 years: A GIMEMA Lazio Working Group experience in a retrospective case-control study.
Rago A; Annibali O; Tomarchio V; Coppetelli U; Fazio F; Cupelli L; Fiorini A; Piciocchi A; Tafuri A; Caravita di Toritto T
Eur J Haematol; 2022 Sep; 109(3):250-256. PubMed ID: 35617025
[TBL] [Abstract][Full Text] [Related]
27. [Early immune reconstitution after hematopoietic stem cell transplantation].
Zhu MX; Wan WL; Li HS; Wang J; Wang YF; Hu K; Ke XY
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Jun; 48(3):515-22. PubMed ID: 27318917
[TBL] [Abstract][Full Text] [Related]
28. [Analysis of Curative Efficacy of Different Chemotherapy Regimen Combined with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation on Multiple Myeloma].
Wang CB; Bai H; Xi R; Pan YZ; Wu T; Xu SF; Zhang Q; Zhou JM; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1675-1680. PubMed ID: 30501703
[TBL] [Abstract][Full Text] [Related]
29. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.
Auner HW; Szydlo R; van Biezen A; Iacobelli S; Gahrton G; Milpied N; Volin L; Janssen J; Nguyen Quoc S; Michallet M; Schoemans H; El Cheikh J; Petersen E; Guilhot F; Schönland S; Ahlberg L; Morris C; Garderet L; de Witte T; Kröger N;
Bone Marrow Transplant; 2013 Nov; 48(11):1395-400. PubMed ID: 23708704
[TBL] [Abstract][Full Text] [Related]
30. Immune reconstitution and production of intracellular cytokines in T lymphocyte populations following autologous peripheral blood stem cell transplantation.
Schlenke P; Sheikhzadeh S; Weber K; Wagner T; Kirchner H
Bone Marrow Transplant; 2001 Aug; 28(3):251-7. PubMed ID: 11535992
[TBL] [Abstract][Full Text] [Related]
31. Prognostic outcomes of cytomegalovirus reactivation after autologous stem cell transplantation.
Lee BH; Jeon MJ; Yu ES; Kang KW; Kim DS; Lee SR; Park Y; Sung HJ; Choi CW; Kim BS
Int J Med Sci; 2023; 20(2):186-193. PubMed ID: 36794152
[No Abstract] [Full Text] [Related]
32. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.
Schaap N; Schattenberg A; Mensink E; Preijers F; Hillegers M; Knops R; Pennings A; Boezeman J; Geurts van Kessel A; de Pauw B; de Witte T
Leukemia; 2002 Jan; 16(1):13-21. PubMed ID: 11840258
[TBL] [Abstract][Full Text] [Related]
33. Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only.
LeBlanc R; Claveau JS; Ahmad I; Delisle JS; Bambace N; Bernard L; Cohen S; Kiss T; Lachance S; Landais S; Roy DC; Sauvageau G; Roy J
Clin Transplant; 2020 Dec; 34(12):e14099. PubMed ID: 32981146
[TBL] [Abstract][Full Text] [Related]
34. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.
Giralt S; Costa LJ; Maloney D; Krishnan A; Fei M; Antin JH; Brunstein C; Geller N; Goodman S; Hari P; Logan B; Lowsky R; Qazilbash MH; Sahebi F; Somlo G; Rowley S; Vogl DT; Vesole DH; Pasquini M; Stadtmauer E
Biol Blood Marrow Transplant; 2020 Apr; 26(4):798-804. PubMed ID: 31756536
[TBL] [Abstract][Full Text] [Related]
35. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
[TBL] [Abstract][Full Text] [Related]
36. Factors influencing lymphocyte reconstitution after allogeneic hematopoietic stem cell transplantation in children.
Bae KW; Kim BE; Koh KN; Im HJ; Seo JJ
Korean J Hematol; 2012 Mar; 47(1):44-52. PubMed ID: 22479277
[TBL] [Abstract][Full Text] [Related]
37. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.
Nair AP; Walker P; Kalff A; Bergin K; Hocking J; Avery S; Curtis DJ; Patil S; Das T; Klarica D; Morgan S; Muirhead J; Gorniak M; Reynolds J; Spencer A
Bone Marrow Transplant; 2017 Jun; 52(6):839-845. PubMed ID: 28319080
[TBL] [Abstract][Full Text] [Related]
38. Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies.
Leng S; Moshier E; Tremblay D; Hu L; Biran N; Barman N; Parekh S; Cho H; Madduri D; Richter J; Barlogie B; Jagannath S; Chari A
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e734-e751. PubMed ID: 32660906
[TBL] [Abstract][Full Text] [Related]
39. Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation.
Kameoka J; Sato T; Torimoto Y; Sugita K; Soiffer RJ; Schlossman SF; Ritz J; Morimoto C
Blood; 1995 Feb; 85(4):1132-7. PubMed ID: 7849301
[TBL] [Abstract][Full Text] [Related]
40. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
Varma A; Biritxinaga L; Saliba RM; Stich M; Jauch SF; Afrough A; Honhar M; Popat UR; Shafi MA; Shah N; Bashir Q; Dinh Y; Hosing C; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2017 Apr; 23(4):581-587. PubMed ID: 28063964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
